196 related articles for article (PubMed ID: 33090284)
1. Retrospective analysis for the efficacy and safety of nivolumab in advanced gastric cancer patients according to ascites burden.
Suzuki H; Yamada T; Sugaya A; Ueyama S; Yamamoto Y; Moriwaki T; Hyodo I
Int J Clin Oncol; 2021 Feb; 26(2):370-377. PubMed ID: 33090284
[TBL] [Abstract][Full Text] [Related]
2. Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival.
Ota Y; Takahari D; Suzuki T; Osumi H; Nakayama I; Oki A; Wakatsuki T; Ichimura T; Ogura M; Shinozaki E; Suenaga M; Chin K; Yamaguchi K
Cancer Chemother Pharmacol; 2020 Feb; 85(2):265-272. PubMed ID: 31907646
[TBL] [Abstract][Full Text] [Related]
3. [Neutrophil-Lymphocyte Ratio as a Prognostic Indicator in Patients Treated with Nivolumab for Gastric Cancer].
Fujita K; Haruki N; Kurehara H; Ochi N; Yamakawa Y; Harata S; Tsumoto C; Tsuji T; Ito T; Izumi A; Usui R; Shinoda N
Gan To Kagaku Ryoho; 2020 Jun; 47(6):923-926. PubMed ID: 32541169
[TBL] [Abstract][Full Text] [Related]
4. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
[TBL] [Abstract][Full Text] [Related]
5. Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan.
Aoki M; Kadowaki S; Takahashi N; Suzuki T; Oshima K; Ando T; Yamamoto Y; Kawakami K; Kito Y; Matsumoto T; Shimozaki K; Miyazaki Y; Yamaguchi T; Nagase M; Tamura T; Amanuma Y; Esaki T; Miura Y; Akiyoshi K; Baba E; Makiyama A; Negoro Y; Nakashima K; Sugimoto N; Nagashima K; Shoji H; Boku N
Gastric Cancer; 2023 Jan; 26(1):132-144. PubMed ID: 36316527
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors to predict the survival in patients with advanced gastric cancer who receive later-line nivolumab monotherapy-The Asahikawa Gastric Cancer Cohort Study (AGCC).
Tanaka K; Tanabe H; Sato H; Ishikawa C; Goto M; Yanagida N; Akabane H; Yokohama S; Hasegawa K; Kitano Y; Sugiyama Y; Uehara K; Kobayashi Y; Murakami Y; Kunogi T; Sasaki T; Takahashi K; Ando K; Ueno N; Kashima S; Moriichi K; Sato K; Yuzawa S; Tanino M; Taruiishi M; Sumi Y; Mizukami Y; Fujiya M; Okumura T
Cancer Med; 2022 Jan; 11(2):406-416. PubMed ID: 34845844
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of nivolumab for advanced gastric cancer patients with poor performance statuses.
Matsumoto T; Yamamoto Y; Kuriona Y; Okazaki U; Kimura S; Miura K; Tsuduki T; Watanabe T; Mastumoto Y; Takatani M
BMC Cancer; 2020 Jul; 20(1):684. PubMed ID: 32698781
[TBL] [Abstract][Full Text] [Related]
8. Lymphocyte-to-Monocyte Ratio Is a Predictive Biomarker of Response to Treatment with Nivolumab for Gastric Cancer.
Tokumaru S; Koizumi T; Sekino Y; Takeuchi N; Nakata S; Miyagawa Y; Kitazawa M; Muranaka F; Nakamura S; Koyama M; Yamamoto Y; Ehara T; Hondo N; Soejima Y
Oncology; 2021; 99(10):632-640. PubMed ID: 34280933
[TBL] [Abstract][Full Text] [Related]
9. Distribution of therapeutic monoclonal antibodies into ascites in advanced gastric cancer patients with peritoneal metastasis: case reports and literature review.
Kaneko T; Doki K; Yamada T; Yamamoto Y; Moriwaki T; Suzuki Y; Homma M
Cancer Chemother Pharmacol; 2022 Nov; 90(5):421-426. PubMed ID: 36180639
[TBL] [Abstract][Full Text] [Related]
10. Cancer Cachexia Reduces the Efficacy of Nivolumab Treatment in Patients With Advanced Gastric Cancer.
Fujii H; Makiyama A; Iihara H; Okumura N; Yamamoto S; Imai T; Arakawa S; Kobayashi R; Tanaka Y; Yoshida K; Suzuki A
Anticancer Res; 2020 Dec; 40(12):7067-7075. PubMed ID: 33288604
[TBL] [Abstract][Full Text] [Related]
11. Association Between Immune-Related Adverse Events and the Prognosis of Patients with Advanced Gastric Cancer Treated with Nivolumab.
Kono Y; Choda Y; Nakagawa M; Miyahara K; Ishida M; Kubota T; Seo K; Hirata T; Obayashi Y; Gotoda T; Moritou Y; Okikawa Y; Iwamoto Y; Okada H
Target Oncol; 2021 Mar; 16(2):237-248. PubMed ID: 33475927
[TBL] [Abstract][Full Text] [Related]
12. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Prognostic Factors for Unresectable or Recurrent Gastric Cancer Treated with Nivolumab.
Ishido K; Tanabe S; Katada C; Ishibashi Y; Kitahara G; Onoue M; Kubota Y; Furue Y; Wada T; Watanabe A; Kusano C
J Gastrointest Cancer; 2023 Jun; 54(2):485-491. PubMed ID: 35437632
[TBL] [Abstract][Full Text] [Related]
14. Systemic inflammatory response and nutritional biomarkers as predictors of nivolumab efficacy for gastric cancer.
Namikawa T; Yokota K; Tanioka N; Fukudome I; Iwabu J; Munekage M; Uemura S; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
Surg Today; 2020 Nov; 50(11):1486-1495. PubMed ID: 32542414
[TBL] [Abstract][Full Text] [Related]
15. First-line bolus 5-fluorouracil plus leucovorin for peritoneally disseminated gastric cancer with massive ascites or inadequate oral intake.
Hara H; Kadowaki S; Asayama M; Ooki A; Yamada T; Yoshii T; Yamaguchi K
Int J Clin Oncol; 2018 Apr; 23(2):275-280. PubMed ID: 29039072
[TBL] [Abstract][Full Text] [Related]
16. Chronological Changes in Neutrophil/lymphocyte Ratio in Advanced Gastric Cancer Patients Treated with Nivolumab: a Report of Nine Cases.
Nakamura N; Kinami S; Fujita J; Kaida D; Tomita Y; Miyata T; Fujita H; Takamura H; Ueda N; Kosaka T
Asian Pac J Cancer Prev; 2020 Oct; 21(10):2955-2960. PubMed ID: 33112554
[TBL] [Abstract][Full Text] [Related]
17. Impact of the Neutrophil-to-Lymphocyte Ratio on the Survival of Patients with Gastric Cancer Treated with Nivolumab Monotherapy.
Yamada T; Hayashi T; Inokuchi Y; Hayashi K; Watanabe H; Komori K; Kano K; Shimoda Y; Fujikawa H; Shiozawa M; Morinaga S; Rino Y; Masuda M; Ogata T; Oshima T
Target Oncol; 2020 Jun; 15(3):317-325. PubMed ID: 32319020
[TBL] [Abstract][Full Text] [Related]
18. The Efficacy and Safety of Nivolumab Plus mFOLFOX6 in Gastric Cancer with Severe Peritoneal Metastasis.
Nakayama Y; Ando T; Takahashi N; Tsukada K; Takagi H; Goto Y; Nakaya A; Nakada N; Yoshita H; Motoo I; Ueda A; Ueda Y; Sakumura M; Kajiura S; Ogawa K; Hosokawa A; Yasuda I
J Clin Med; 2024 Jan; 13(3):. PubMed ID: 38337528
[TBL] [Abstract][Full Text] [Related]
19. High intramuscular adipose tissue content was a favorable prognostic factor in patients with advanced gastric cancer treated with nivolumab monotherapy.
Tanaka T; Miwa K; Shimotsuura Y; Nagasu S; Shigyou H; Hirota K; Koya S; Akagi Y; Kawaguchi T
J Gastroenterol Hepatol; 2023 Oct; 38(10):1760-1767. PubMed ID: 37225648
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer.
Sasaki A; Nakamura Y; Mishima S; Kawazoe A; Kuboki Y; Bando H; Kojima T; Doi T; Ohtsu A; Yoshino T; Kuwata T; Akimoto T; Shitara K
Gastric Cancer; 2019 Jul; 22(4):793-802. PubMed ID: 30627987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
